




Figure 1



Scheme 3

Figure 4

A

Catalytic
Site

N-lobe

C-lobe

B

Tyr904

Pro906

Asp967

Asp967




Figure 3











Figure 4




A





B




Protein Tyrosine Kinase	Residue at Region A	Residue at Region B	Residue at Region C	Residue at Region D	Residue at Region E	Residue at Region F
JAK3	Pro906	Tyr904	Leu905	Met902	Ala966	Asp912
JAK2	Pro933	Tyr931	Leu932	Met929	Gly993	Asp939
JAK1	Pro948	Phe946	Leu947	Met944	Gly1008	Glu954
BTK	Ala478	Tyr476	Met477	Thr474	Ser538	Asn484
SYK	Glu342	Met340	Ala341	Met338	Ser403	Lys348
HCK	Ala342	Phe340	Met341	Ala342	Ala403	Asp348
LYN	Ala323	Tyr321	Met322	Ala323	Ala384	Asp329
IRK	Ala1080	Leu1078	Met1079	Met1076	Gly1149	Ser1086




WFI-P132	-	-	-	+	+	+	-	-	-	-	-	-
WFI-P131	-	-	-	-	-	-	+	+	+	-	-	-
WFI-P154	-	-	-	-	-	-	-	-	-	+	+	+
IL-2	-	+	-	-	+	-	-	+	-	-	+	-
IL-3	-	-	+	-	-	+	-	-	+	-	-	+
Lane	1	2	3	4	5	6	7	8	9	10	11	12












B.1 Con



B.2 WHI-P131



A



B






Figure 2. Gel electrophoresis of DNA samples.











Figure 17



2023-10-23 14:30:00



Figure 15






1120011

61



61

10563B-DD-E9501



1, 1, 2, 4, 6, 1



Control

UVB

UVB + DDE9501

Figure
21


O.D. 550




P131

- 0
- ▨ 0.1
- ▩ 1
- 10
- ▤ 50

Figure 6c



- WHI-P131 (n=9)
- ◇— WHI-P132 (n=9)
- Vehicle Control (n=51)
- Syngeneic (n=19)
- *--- Irradiation Controls (n=)
- ◆--- Cyclosporin A (n=15)
- △--- Methotrexate (n=16)







Figure 25



00000000000000000000

WHI-P131 (60 mg/kg/day) - effects on GVHD development

Cumulative proportion surviving


<u>Group</u>	<u>n</u>	<u>Cumulative proportion surviving</u>			<u>median survival (d)</u>	<u>Logrank p value</u>	
		<u>30</u>	<u>60</u>	<u>90</u>		vs. Control	vs. WHI-P
CONTROL	51	90.2 ± 4.2	17.6 ± 5.3	2.0 ± 1.9	44		
WHI-P131	9	100 ± 0	77.8 ± 13.9	33.3 ± 15.7	82	0.0003	
WHI-P132	9	88.9 ± 10.5	11.1 ± 10.5	0 ± 0	44	0.485	
Methotrexate	16	93.8 ± 6.1	56.2 ± 12.4	25.0 ± 10.8	63.5	0.0009	0.356
Methotrexate + WHI-P131	13	100 ± 0	76.9 ± 11.7	61.5 ± 13.5	87	<0.0001	0.320
Cyclosporine A	15	73.3 ± 11.4	26.7 ± 11.4	13.3 ± 8.8	45	0.493	0.029
Cyclosporine A + WHI-P131	15	80.0 ± 10.3	33.3 ± 12.2	20.0 ± 10.3	51	0.198	0.062

Methotrexate vs.

Methotrexate + WHI-P131

0.062

20






Figure 29




Figure 50




Figure 31




Figure 32




Figure 33




Figure 37




Figure 35




Figure 36






Figure 51











Figure 70







42